Prelude Therapeutics (PRLD) Change in Account Payables (2019 - 2026)

Prelude Therapeutics has disclosed Change in Account Payables across 8 years of filings, most recently posting -$1.9 million for Q1 2026.

• Change in Account Payables for Q1 2026 came in at -$1.9 million, up 1.62% year-over-year; the trailing twelve-month figure through Mar 2026 was -$3.9 million (down 608.77% YoY), and the FY2025 annual result was -$3.9 million, down 218.55% from the prior year.
• Change in Account Payables came in at -$1.9 million for Q1 2026 at Prelude Therapeutics, down from $1.3 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $3.7 million in Q3 2022 to a low of -$3.2 million in Q4 2022.
• The 5-year median for Change in Account Payables is -$465000.0 (2023), against an average of -$300529.4.
• Across the five-year window, Change in Account Payables jumped 18600.0% in 2023 and tumbled 1040.38% in 2025, its largest moves.
• Prelude Therapeutics' Change in Account Payables stood at -$3.2 million in 2022, then jumped by 85.65% to -$465000.0 in 2023, then jumped by 489.25% to $1.8 million in 2024, then dropped by 29.78% to $1.3 million in 2025, then slumped by 247.84% to -$1.9 million in 2026.
• The last three Change in Account Payables figures came in at -$1.9 million (Q1 2026), $1.3 million (Q4 2025), and -$2.4 million (Q3 2025), per Business Quant data.